title: The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
abstract: BACKGROUND
  Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is a bifunctional protein that has been implicated in both control of cell division and inhibition of apoptosis.
  
  
  METHODS
  This review specially focuses on clinical and experimental data on the relevance of survivin in radiooncology and its role as a therapeutic target to radiosensitize tumor cells.
  
  
  RESULTS
  As compared to normal tissue, survivin is overexpressed in tumors and appears to be closely related to tumor malignancy and treatment response. In addition, survivin is involved in the resistance of tumor cells to both chemotherapy and ionising irradiation. Due to these properties, survivin has been proposed as an attractive target for anticancer therapies. Several preclinical studies have demonstrated that suppression of survivin, by the use of antisense oligonucleotides, small interfering RNAs, ribozymes and the application of dominant negative mutants, increases apoptosis, diminishes tumor cell survival and reduces tumor growth potential.
  
  
  CONCLUSIONS
  Survivin displays a relevant prognostic and predictive factor as well as a promising molecular target to improve the effectiveness of radiotherapy.
authors.affiliation: Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt am Main, Germany. gianni.capalbo@kgu.de
authors.forename: Gianni
authors.initials: G
authors.lastname: Capalbo
authors.forename: Claus
authors.initials: C
authors.lastname: Rödel
authors.forename: Roland H
authors.initials: RH
authors.lastname: Stauber
authors.forename: Shirley K
authors.initials: SK
authors.lastname: Knauer
authors.forename: Matthias
authors.initials: M
authors.lastname: Bache
authors.forename: Matthias
authors.initials: M
authors.lastname: Kappler
authors.forename: Franz
authors.initials: F
authors.lastname: Rödel
mesh_terms: D017209:Apoptosis / Q000528:radiation effects; D051017:Apoptosis Regulatory Proteins; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000502:physiology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000502:physiology*; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D016376:Oligonucleotides, Antisense; D011379:Prognosis; D018787:Radiation Oncology; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D000077022:Survivin; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured / Q000528:radiation effects
chemical_list: D051017:Apoptosis Regulatory Proteins; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D000077022:Survivin